Hypercoagulable States

Classification: Inherited or acquired conditions that shift the balance of hemostasis toward thrombosis through changes in blood flow, the vessel wall, or the coagulation proteins themselves (Davoren & Hsu, 2019; Norris, 2020).

Key diagnostic discriminator: The circumstances of the first clot. Thrombosis at a young age, without a provoking event, at an unusual site, recurrently, or with a strong family history raises concern for an inherited thrombophilia (Davoren & Hsu, 2019).

Clinical priority: Venous thromboembolism can progress to pulmonary embolism. Thrombosis with a falling platelet count during heparin therapy suggests heparin-induced thrombocytopenia, and arterial and venous thrombosis with pregnancy loss suggests antiphospholipid syndrome (Davoren & Hsu, 2019; Norris, 2020).

Etiology and Risk Factors

Virchow described three contributors to abnormal clot formation: slowed blood flow, injury or inflammation of the vessel wall, and changes in the blood itself. Persistent changes in any part of this triad define a hypercoagulable state (Davoren & Hsu, 2019).

Inherited Thrombophilias

Inherited thrombophilias are autosomal dominant, so heterozygous carriers are affected. Most produce only a moderate reduction, about 50%, in the relevant protein. Representative prevalence and relative-risk estimates include (Davoren & Hsu, 2019):

  • Factor V Leiden (activated protein C resistance): Most common; 3% to 7% of the general population is heterozygous. Heterozygotes have a 3- to 5-fold increased risk and homozygotes at least a 20- to 50-fold increased risk.
  • Prothrombin G20210A mutation: Probably the second most common; raises prothrombin levels and increases risk 2- to 3-fold.
  • Protein C deficiency: Up to 1 in 200 people are heterozygous; risk is increased 4- to 6-fold. The homozygous form causes neonatal purpura fulminans.
  • Protein S deficiency: Increases risk 1- to 10-fold; the homozygous form is severe.
  • Antithrombin deficiency: About 1 in 2000 people; increases lifetime risk 5- to 10-fold (Davoren & Hsu, 2019).

Acquired Risk Factors

Acquired risk factors include (Huynh et al., 2026; Norris, 2020):

  • Previous venous thromboembolism, the strongest known risk factor
  • Immobility and prolonged bed rest
  • Major surgery, especially hip and knee replacement
  • Trauma, particularly fractures of the pelvis, hip, or leg
  • Indwelling venous catheters
  • Heart failure and acute myocardial infarction
  • Malignancy and ongoing chemotherapy
  • Pregnancy and the postpartum period
  • Estrogen-containing contraceptives, estrogen replacement therapy, and selective estrogen receptor modulators
  • Obesity
  • Increasing age, especially after 45 years
  • Antiphospholipid antibodies
  • Heparin-induced thrombocytopenia
  • Myeloproliferative disorders and increased platelet counts
  • Prolonged car or air travel

Conditions that increase platelet function, including atherosclerosis, diabetes, smoking, and elevated lipids, predispose mainly to arterial thrombosis (Norris, 2020).

Epidemiology and Clinical Context

Most thromboembolic events encountered in practice are secondary to acquired risk. Inherited thrombophilias are relatively rare in the general population but account for a substantial share of thrombosis in young patients, and factor V Leiden heterozygotes probably represent more than one-third of patients with familial thrombosis (Davoren & Hsu, 2019).

Only a minority of carriers develop symptomatic thrombosis. Heterozygotes who clot usually do so when a second risk factor is present, such as surgery, immobilization, pregnancy, or estrogen use (Davoren & Hsu, 2019). About 20% to 25% of patients presenting with apparently primary venous thromboembolism are found to have an occult malignancy (Norris, 2020).

Pathophysiology

Coagulation is controlled by natural anticoagulants that act at specific checkpoints. Activated protein C, generated when thrombin binds endothelial thrombomodulin, cleaves and inactivates factors Va and VIIIa, with protein S as its cofactor. Antithrombin binds and blocks thrombin and factors IXa, Xa, and XIa, an action accelerated up to 2000-fold by heparin. Factor Va is a key control point because it is required for the prothrombinase complex that generates the thrombin burst (Davoren & Hsu, 2019).

Most inherited thrombophilias are failures of anticoagulation rather than excess procoagulant activity (Davoren & Hsu, 2019):

  • In factor V Leiden, a single amino acid substitution alters the site where activated protein C cleaves factor Va, so factor Va continues to drive thrombin generation.
  • In protein C, protein S, and antithrombin deficiencies, the inhibitor is reduced in amount or function.
  • The prothrombin G20210A mutation is the exception, increasing prothrombin levels and thrombin generation.

Estrogen raises clotting factor levels and induces activated protein C resistance, which helps explain the thrombotic risk of estrogen therapy and pregnancy (Huynh et al., 2026). Cancer cells release tissue factor, and immobility, sepsis, and chemotherapy add to the risk in patients with malignancy (Norris, 2020).

Antiphospholipid syndrome is caused by autoantibodies, primarily IgG, against phospholipid-binding proteins. It can occur alone or with systemic lupus erythematosus. The exact mechanism is not established, and a second event such as vascular injury or infection-related endothelial activation may be needed for thrombosis to occur (Norris, 2020).

Arterial thrombi tend to form under turbulent flow and are composed largely of platelets. Venous thrombi form under stasis and consist of platelets within a larger fibrin mesh (Norris, 2020).

Clinical Manifestations

Deep vein thrombosis (DVT) of the legs is the most common presentation, whether or not a thrombophilia is present, because leg veins combine slow, high-capacity flow with frequent exposure to injury (Davoren & Hsu, 2019). DVT manifestations may include (Davoren & Hsu, 2019; Huynh et al., 2026; Norris, 2020):

  • Unilateral leg pain and swelling that persists after a night’s sleep
  • Warmth, redness, or discoloration below the level of the clot
  • Calf tenderness
  • Prominent superficial collateral veins
  • Normal arterial pulses and distal perfusion
  • Swelling of the entire extremity with iliofemoral thrombosis

Many DVTs are asymptomatic, and physical examination signs, including the Homans sign, are unreliable (Huynh et al., 2026). Pulmonary embolism typically presents with acute-onset dyspnea and hypoxemia (Davoren & Hsu, 2019). See Pulmonary Embolism.

Features that suggest an inherited thrombophilia include (Davoren & Hsu, 2019):

  • First thrombosis at a young age
  • Recurrent thrombosis
  • Thrombosis without a provoking event
  • Family history of thrombosis
  • Thrombosis at unusual sites, such as the cerebral venous sinuses or mesenteric veins

Arterial thrombosis is extremely rare with inherited thrombophilias (Davoren & Hsu, 2019). Antiphospholipid syndrome presents with venous thrombosis in up to half of patients, arterial thrombosis that most often affects the brain as transient ischemic attack or stroke, thrombocytopenia, and recurrent pregnancy loss (Norris, 2020).

Diagnostic Evaluation

Clinical Probability

Signs and symptoms of venous thromboembolism are nonspecific, so objective testing is required. The Wells criteria estimate the pretest probability of DVT and pulmonary embolism (PE) (Huynh et al., 2026).

D-Dimer

D-dimer is a sensitive but nonspecific marker of fibrin breakdown. In a patient with low clinical probability, a negative D-dimer can exclude DVT. A positive result, or moderate or high clinical probability, calls for imaging. Hospitalized patients generally proceed directly to imaging (Huynh et al., 2026).

Imaging

Duplex ultrasonography is the most commonly used test for DVT and is preferred over venography, the historical gold standard, because venography is invasive (Huynh et al., 2026).

Initial Laboratory Testing

Initial evaluation includes a complete blood count (CBC) with differential, prothrombin time and international normalized ratio (PT/INR), activated partial thromboplastin time (aPTT), serum chemistries with renal and liver function, and urinalysis (Huynh et al., 2026).

Thrombophilia Testing

Testing is considered for patients who are young, have recurrent or unprovoked thrombosis, have clots at unusual sites, or have a strong family history (Davoren & Hsu, 2019).

  • Factor V Leiden and the prothrombin G20210A mutation are identified by polymerase chain reaction.
  • Protein C, protein S, and antithrombin are assessed with quantitative antigen assays and functional activity assays, because some deficiencies involve a normal amount of poorly functioning protein.
  • Protein C and protein S are vitamin K dependent, so warfarin lowers their measured levels and complicates interpretation during therapy (Davoren & Hsu, 2019).

Additional Testing

Depending on the presentation, evaluation may include antiphospholipid antibody testing, age-appropriate cancer screening, and assessment for heparin-induced thrombocytopenia in patients receiving heparin (Huynh et al., 2026; Norris, 2020).

Expected Findings

Findings that support a hypercoagulable state include (Davoren & Hsu, 2019; Huynh et al., 2026; Norris, 2020):

  • Objectively confirmed venous thrombosis
  • Positive D-dimer during acute thrombosis
  • Thrombosis at a young age, recurrence, or an unusual site
  • A positive family history
  • Factor V Leiden or prothrombin G20210A mutation on genetic testing
  • Reduced protein C, protein S, or antithrombin level or activity
  • Antiphospholipid antibodies with thrombosis or pregnancy loss

Differential Diagnosis

Chronic Venous Insufficiency

Chronic venous insufficiency is the most common cause of unilateral leg swelling and usually develops gradually, often with varicose veins (Seller & Symons, 2018).

Cellulitis

Cellulitis produces warmth, tenderness, and erythema of the leg and can mimic DVT, particularly in patients with diabetes (Seller & Symons, 2018).

Ruptured Baker Cyst or Muscle Injury

A ruptured Baker cyst, sometimes called pseudophlebitis, or a ruptured gastrocnemius muscle can cause sudden painful calf swelling (Seller & Symons, 2018).

Post-Thrombotic Syndrome

Damage to venous valves after a previous DVT causes chronic swelling, pain, skin discoloration, and ulceration that must be distinguished from recurrent acute thrombosis (Huynh et al., 2026).

Systemic Edema States

Heart failure, nephrotic syndrome, cirrhosis, and medications such as calcium channel blockers usually produce bilateral rather than unilateral leg swelling (Seller & Symons, 2018).

Findings That Reduce Diagnostic Probability

Few findings exclude venous thrombosis or thrombophilia by themselves. The following findings should lower their position in the differential or prompt evaluation for an alternative:

  • A negative D-dimer in a patient with low clinical probability makes DVT unlikely (Huynh et al., 2026).
  • Bilateral, symmetric leg swelling favors a systemic edema state over DVT (Seller & Symons, 2018).
  • A clearly provoked first clot in an older patient with a major transient risk factor makes an inherited thrombophilia less likely to change management (Davoren & Hsu, 2019; Huynh et al., 2026).
  • Arterial rather than venous thrombosis argues against an inherited thrombophilia and should prompt consideration of antiphospholipid syndrome, heparin-induced thrombocytopenia, or atherosclerotic disease (Davoren & Hsu, 2019; Norris, 2020).

Treatment and Management

Anticoagulation

Treatment principles include (Huynh et al., 2026):

  • Treatment is organized into an acute phase (the first 5 to 10 days), a long-term phase (the first 3 months), and an extended phase beyond 3 months.
  • Initial therapy uses a rapidly acting direct oral anticoagulant, such as apixaban or rivaroxaban, or a parenteral agent such as low-molecular-weight heparin, unfractionated heparin, or fondaparinux.
  • When warfarin is used, it overlaps the parenteral agent for at least 5 days and until the INR is at least 2 for 24 to 48 hours.
  • Dabigatran and edoxaban are started after 5 to 10 days of parenteral therapy.
  • Thrombolysis is reserved for pulmonary embolism with shock or hypotension, or massive DVT threatening the limb (Huynh et al., 2026).

Duration

Anticoagulation continues for at least 3 months. Venous thromboembolism provoked by a transient risk factor such as surgery or trauma is usually treated for 3 months. Unprovoked venous thromboembolism carries a recurrence risk of at least 10% at 1 year and 30% at 5 years, so most of these patients are candidates for extended or indefinite therapy if bleeding risk is acceptable. The decision weighs recurrence risk, bleeding risk, and patient preference and is revisited periodically (Huynh et al., 2026).

Special Considerations

Special considerations include (Huynh et al., 2026; Norris, 2020):

  • Rivaroxaban may be inferior to warfarin in triple-positive antiphospholipid syndrome.
  • Patients with protein C or protein S deficiency are at higher risk of warfarin-induced skin necrosis, which typically appears during the first week of therapy in fatty areas such as the abdomen, buttocks, and breasts.
  • Low-molecular-weight heparin is preferred during pregnancy (Huynh et al., 2026).
  • For patients with antiphospholipid syndrome, risk reduction includes smoking cessation and avoidance of estrogen-containing contraceptives (Norris, 2020).

Prevention

Every hospitalized patient should be assessed for venous thromboembolism risk at admission, at transitions of care, and before discharge. The Padua score is used for medical patients and the Caprini score for surgical patients, and bleeding risk is weighed before pharmacologic prophylaxis is chosen. Mechanical prophylaxis is used when pharmacologic prophylaxis is contraindicated (Huynh et al., 2026).

Complications and Red Flags

Urgent escalation is required for:

  • Signs of pulmonary embolism, including sudden dyspnea, pleuritic chest pain, hypoxemia, syncope, or hypotension
  • Massive leg swelling with limb-threatening ischemia
  • New thrombosis with a falling platelet count during heparin therapy
  • Thrombosis at an unusual site, such as the cerebral venous sinuses or mesenteric veins
  • Major bleeding during anticoagulation
  • Painful skin lesions early in warfarin therapy

Long-term complications include recurrent venous thromboembolism and post-thrombotic syndrome (Huynh et al., 2026).

Clinical Reasoning Priorities

After confirming venous thromboembolism, determine whether the event was provoked before pursuing thrombophilia testing. Provocation status, bleeding risk, and patient preference more often determine anticoagulation duration than inherited-test results (Davoren & Hsu, 2019; Huynh et al., 2026).

Content last reviewed:

References

Davoren, J. B., & Hsu, G. (2019). Blood disorders. In G. D. Hammer & S. J. McPhee (Eds.), Pathophysiology of disease: An introduction to clinical medicine (8th ed.). McGraw-Hill Education.

Huynh, N. S., Cantrell, M., & Lee, J. C. (2026). Venous thromboembolism. In M. A. Chisholm-Burns, P. M. Malone, J. M. Kolesar, K. C. Lee, P. B. Bookstaver, & K. R. Matthias (Eds.), Pharmacotherapy principles & practice (7th ed.). McGraw Hill.

Norris, T. L. (2020). Porth’s essentials of pathophysiology (5th ed.). Wolters Kluwer.

Seller, R. H., & Symons, A. B. (2018). Differential diagnosis of common complaints (7th ed.). Elsevier.